Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
about
Follicular lymphoma: 2012 update on diagnosis and managementThe Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell TransplantationNonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphomaFollicular lymphoma: 2014 update on diagnosis and managementHematopoietic cell transplantation for B-cell lymphoma: an updateAllogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older PatientsReappraising the timing of transplant for indolent non-Hodgkin lymphomas.Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignanciesReduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.Controversies and recent advances in hematopoietic cell transplantation for follicular non-hodgkin lymphomaLong-term outcome after autologous or allogeneic stem cell transplantation in patients with recurrent follicular lymphoma.Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party.Hematopoietic stem cell transplantation for the management of follicular lymphomaOutcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma.The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months.Role of hematopoietic stem cell transplant in the management of follicular lymphoma.Long-term outcomes of high dose treatment and autologous stem cell transplantation in follicular and mantle cell lymphomas - a single centre experience.Allogeneic stem cell transplantation in follicular lymphoma.Hematopoietic cell transplantation for lymphomas.Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?Managing newly diagnosed follicular lymphoma: state of the art and future perspectives.Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.Autologous and allogeneic hematopoietic stem cell transplantation in follicular lymphoma.Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma.Follicular lymphoma: 2015 update on diagnosis and management.Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma.Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group.Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure.Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?Follicular lymphoma: 2018 update on diagnosis and management.Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.Early Relapse in Follicular Lymphoma: High Risks and High Stakes.
P2860
Q22252956-42D909B9-5942-4A57-B1C8-AAC56CC9EF35Q26740251-E4287935-BD19-4E08-8564-153DA34A48E5Q26999011-B1718922-5992-4CC6-9D1B-BE56702A3F67Q27021850-D5AD042E-400E-45FB-B839-35DA0E57A22DQ27026617-B3FE85A1-2CC7-4D78-99EF-767136E17442Q28066710-5660F166-6257-4D7B-A11D-42F10D43CE29Q30248407-F6348064-78EF-4DD0-8B5A-5EF9FC10CD38Q33795160-6DD56EAA-8EE8-4876-8782-D7DB57992EF6Q35100217-3E612AD5-3870-4FDC-8BE5-D5B2267A79B5Q35140326-D57312FD-E8B8-46A4-8224-06E8B088E492Q36264884-E9E44656-B0BB-43F8-9FC4-E993322E6068Q36336614-63FDF9ED-77A0-42D7-9A2D-D681D606610FQ36837761-3077A9E1-9C1E-4AAA-98E5-388A68CBA2ACQ36967098-3A4F8DE1-DE98-42A8-B5FF-AFC3214101B1Q37194061-FD9B6C5F-D35C-4B2A-9C29-465463F9DE27Q37212916-EC87EDD7-94D7-4222-8DAC-F3325DA481DEQ37312857-000AA2C2-1C12-4964-9FF3-8068C97C1A3CQ37533977-AA51EB7B-8B7F-48DF-A3DA-3261A228313AQ37671462-70AEE01B-281B-4461-8082-C0D187784638Q37887151-31BF0DD1-A907-4867-8494-B29F3D685D6BQ37942817-D882B1A8-7768-4AC7-8B84-02EBD490E62FQ38045706-12B84270-D109-49E4-A8F2-AECB92B2057EQ38088002-F3ED374F-F55B-47A1-BBFD-C19734BF836DQ38387292-1E51C387-F83A-466A-9C9B-9FE3B8B9EFFDQ38619847-D3310F48-B183-4317-9273-4C6AB01E1BDAQ38777460-D713290C-4309-418A-A864-DFC768D1A3D5Q40122693-EDBC3E8F-73DC-4D41-B162-4E38589F6C0EQ40744550-41A9A8BD-8127-4108-80A6-F32BAB572DC0Q44065098-6D816D17-4F5A-4BA4-859B-B7E5392AFAA2Q45330725-E8D8C962-AE76-4F63-9876-5CB91F9788D8Q47174138-4ADA3629-5AF4-4E8F-8C6A-AC7ACAFACEA6Q47219215-1EB96819-A6B6-4106-BD7C-71EB9A246035Q47843221-D993F07F-2CFB-4DEF-86F3-B488147289A6Q49895456-88CBA17F-FB17-4BDE-A9EA-43C070D5C582
P2860
Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Autologous versus reduced-inte ...... nse or first partial response.
@en
type
label
Autologous versus reduced-inte ...... nse or first partial response.
@en
prefLabel
Autologous versus reduced-inte ...... nse or first partial response.
@en
P2093
P2860
P1476
Autologous versus reduced-inte ...... nse or first partial response.
@en
P2093
Brad S Kahl
Christopher Bredeson
Ginna G Laport
Marcie R Tomblyn
Marian Ewell
Mary M Horowitz
Robert S Negrin
Stacey A Goodman
P2860
P304
P356
10.1016/J.BBMT.2010.11.004
P50
P577
2010-11-10T00:00:00Z